AI assistant
Sending…
Alzamend Neuro, Inc. — Director's Dealing 2021
Sep 15, 2021
35321_dirs_2021-09-15_02786a9a-34fe-4214-af14-45100a2fde2a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Alzamend Neuro, Inc. (ALZN)
CIK: 0001677077
Period of Report: 2021-09-13
Reporting Person: GUSTAFSON MARK (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-13 | Common Stock | M | 2778 | — | Acquired | 2778 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-13 | Restricted Stock Grant | $ | M | 2778 | Disposed | 2024-09-13 | Common Stock (2778) | Direct |
Footnotes
F1: Represents the vesting of restricted stock.
F2: Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc.
F3: The restricted stock grant vests in 36 equal monthly installments commencing on September 13, 2021.
More from Alzamend Neuro, Inc.
Proxy Solicitation & Information Statement
2026
Feb 26
Director's Dealing
2025
Dec 30
Director's Dealing
2025
Dec 23
Interim / Quarterly Report
2025
Dec 9
Board/Management Information
2025
Nov 18
Director's Dealing
2025
Oct 24
Regulatory Filings
2025
Oct 14
Director's Dealing
2025
Oct 10
Capital/Financing Update
2025
Oct 9
Director's Dealing
2025
Oct 8